文献速递颈动脉与弓上血管

无症状与症状性中重度颈动脉狭窄的最佳抗血小板治疗:文献综合综述

Optimal Antiplatelet Therapy in Moderate to Severe Asymptomatic and Symptomatic Carotid Stenosis: A Comprehensive Review of the Literature.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2018-11-07

该综述按PRISMA声明检索1988至2018年随机试验,评估无症状或症状性颅外中重度颈动脉狭窄患者的抗血小板方案。结果显示阿司匹林81-325 mg/日可用于预防血管事件,低中剂量优于高剂量,围术期阿司匹林-氯吡格雷似乎安全,但常规双联证据不足。

要点

  • 无症状颈动脉狭窄可推荐阿司匹林81-325 mg/日预防血管事件。
  • 颈动脉内膜切除术后低中剂量阿司匹林优于高剂量预防复发。
  • 症状性狭窄常规阿司匹林-氯吡格雷双联证据不足。

核心结论

  • 阿司匹林81-325 mg/日可用于无症状颈动脉狭窄患者预防血管事件。
  • 颈动脉内膜切除术后低中剂量阿司匹林预防复发优于高剂量。
  • 症状性中重度狭窄常规双联抗血小板证据不足。

研究设计与样本

  • 按PRISMA声明进行的综合文献综述。
  • 检索Medline、Ovid、Embase、Web of Science和Google Scholar 1988至2018年文献。
  • 纳入25项符合标准的随机试验。

主要发现

  • 一项随机对照试验显示阿司匹林与安慰剂在无症状颈动脉狭窄中获益无显著差异。
  • 颈动脉内膜切除术后低中剂量阿司匹林(81-325 mg/日)预防复发优于高剂量(>650 mg/日)。
  • 血管内治疗试验支持围术期使用阿司匹林81-325 mg/日。
  • 围术期阿司匹林-氯吡格雷基于一项预试验,似乎安全。
  • 短期阿司匹林-双嘧达莫或阿司匹林-氯吡格雷在≥50%症状性狭窄中减少微栓子信号效果相当。

关键数值与推荐

  • 无症状颈动脉狭窄推荐阿司匹林81-325 mg/日。
  • 颈动脉内膜切除术后低中剂量阿司匹林(81-325 mg/日)优于高剂量(>650 mg/日)。
  • 血管内治疗围术期使用阿司匹林81-325 mg/日。
  • 症状性≥50%狭窄短期阿司匹林-双嘧达莫或阿司匹林-氯吡格雷减少微栓子信号等效。
  • 不推荐常规阿司匹林-氯吡格雷双联用于减少症状性狭窄复发临床缺血事件。

临床怎么用

  • 无症状颈动脉狭窄患者可每日服用阿司匹林81-325 mg预防血管事件。
  • 颈动脉内膜切除术后选择低中剂量阿司匹林而非高剂量。
  • 血管内治疗围术期使用阿司匹林81-325 mg/日,可考虑联合氯吡格雷。
  • 症状性狭窄不常规使用双联抗血小板预防复发临床缺血事件。

局限性

  • 无症状颈动脉狭窄阿司匹林获益仅基于一项随机对照试验且无显著差异。
  • 围术期阿司匹林-氯吡格雷证据仅来自一项预试验。
  • 常规双联抗血小板减少复发临床缺血事件证据不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Carotid stenosis patients are at risk of vascular events despite antiplatelet therapy. Data on prescribed antiplatelet regimens have not been comprehensively collated from trials to guide optimal therapy in this population. METHODS: This review was conducted in line with the current Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. Medline, Ovid, Embase, Web of Science, and Google Scholar from 1988 to 2018 were searched using the search terms "carotid stenosis", "asymptomatic", "symptomatic", "antiplatelet", and "anti-platelet" to identify randomised trials in patients with asymptomatic or symptomatic extracranial moderate-severe carotid stenosis on any form of antiplatelet therapy in which vascular events and pre specified composite outcome events were reported. RESULTS: Twenty-five studies were judged eligible for inclusion. Data from one randomised controlled trial showed no significant difference in benefit with aspirin versus placebo in asymptomatic carotid stenosis, but it is still reasonable to recommend aspirin (81-325 mg daily) for prevention of vascular events in these patients. Low to medium dose aspirin (81-325 mg daily) is superior to higher doses (>650 mg daily) at preventing recurrent vascular events in patients undergoing endarterectomy. Data from endovascular treatment (EVT) trials support peri-procedural treatment of asymptomatic and symptomatic patients with 81-325 mg of aspirin daily. The use of peri-procedural aspirin-clopidogrel in patients undergoing EVT is based on one pilot trial, but appears safe. Short-term aspirin-dipyridamole or aspirin-clopidogrel treatments are equally effective at reducing micro-embolic signals on transcranial Doppler ultrasound in patients with ≥50% symptomatic carotid stenosis. There is insufficient evidence to recommend routine aspirin-clopidogrel combination therapy to reduce the risk of recurrent clinical ischaemic events in patients with symptomatic moderate-severe carotid stenosis. CONCLUSIONS: This comprehensive review outlines an evidence based approach to antiplatelet therapy in carotid stenosis patients. Future trials should randomise such patients to receive different antiplatelet regimens to assess their efficacy and safety and to optimise peri-procedural and long-term preventive treatment in this patient cohort.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Murphy SJX, Naylor AR, Ricco JB, et al. Optimal Antiplatelet Therapy in Moderate to Severe Asymptomatic and Symptomatic Carotid Stenosis: A Comprehensive Review of the Literature. Eur J Vasc Endovasc Surg. 2018. PMID: 30414802. doi:10.1016/j.ejvs.2018.09.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。